Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug 30;35(4):424-430.
doi: 10.21147/j.issn.1000-9604.2023.04.08.

Focal ablation therapy presents promising results for selectively localized prostate cancer patients

Dechao Feng  1   2 , Dengxiong Li  1 , Yuhan Xiao  1 , Ruicheng Wu  1 , Jie Wang  1 , Chi Zhang  2
Affiliations

Focal ablation therapy presents promising results for selectively localized prostate cancer patients

Dechao Feng et al. Chin J Cancer Res. .

Abstract

Due to its lower risk of consequences when compared to a radical approach, focal treatment is a viable and minimally invasive option for treating specific localized prostate cancer. Although several recent good non-randomized trials have suggested that focused therapy may be an alternative choice for some patients, additional high-quality evidence is needed before it can be made widely available as a conventional treatment. As a result, we have summarized the most recent findings from the 38th Annual European Association of Urology Congress, one of the most renowned annual conferences in the area of urology, regarding focal ablation therapy for patients with localized prostate cancer. Additionally, we also provided clinical trials in progress for researchers to better understand the current research status of this field.

Keywords: Prostate cancer; focal laser ablation; focal ultrasound ablation; targeted microwave ablation.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Varisli L, Tolan V, Cen JH, et al Dissecting the effects of androgen deprivation therapy on cadherin switching in advanced prostate cancer: A molecular perspective. Oncol Res. 2023;30:137–55. doi: 10.32604/or.2022.026074. - DOI - PMC - PubMed
    1. Zhu S, Xu N, Liang J, et al Mutations in epigenetic regulator KMT2C detected by liquid biopsy are associated with worse survival in prostate cancer patients. Oncol Res. 2023;31:605–14. doi: 10.32604/or.2023.028321. - DOI - PMC - PubMed
    1. Megerian MF, Kim JS, Badreddine J, et al Melatonin and prostate cancer: Anti-tumor roles and therapeutic application. Aging Dis. 2023;14:840–57. doi: 10.14336/AD.2022.1010. - DOI - PMC - PubMed

    1. Song Z, Cao Q, Guo B, et al. Overexpression of RACGAP1 by E2F1 promotes neuroendocrine differentiation of prostate cancer by stabilizing EZH2 expression. Aging Dis 2023. [Epub ahead of print]

    1. Yang Y Comments on National guidelines for diagnosis and treatment of prostate cancer 2022 in China (English version) Chin J Cancer Res. 2022;34:456–7. doi: 10.21147/j.issn.1000-9604.2022.05.05. - DOI - PMC - PubMed

LinkOut - more resources